Federica Caggia
Modena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndrome.
Journal: Menopause (New York, N.Y.)
Published: November 18, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.
Journal: NPJ breast cancer
Published: August 28, 2025
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments.
Journal: Breast cancer (Dove Medical Press)
Published: August 23, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
Journal: BMC cancer
Published: March 03, 2024
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges.
Journal: Biomedicines
Published: November 27, 2022
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy.
Journal: Frontiers in oncology
Published: August 10, 2022
Last Updated: 09/26/2026